Tempest Therapeutics, Inc. Profile Avatar - Palmy Investing

Tempest Therapeutics, Inc.

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is cu…

Biotechnology
US, South San Francisco [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Tempest Therapeutics, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Tempest Therapeutics, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Tempest Therapeutics, Inc..

End of TPST's Analysis
CIK: 1544227 CUSIP: 87978U108 ISIN: US87978U1088 LEI: - UEI: -
Secondary Listings
TPST has no secondary listings inside our databases.